CN1057693C - Hepatitis B virus converting negative tablet - Google Patents
Hepatitis B virus converting negative tablet Download PDFInfo
- Publication number
- CN1057693C CN1057693C CN97106065A CN97106065A CN1057693C CN 1057693 C CN1057693 C CN 1057693C CN 97106065 A CN97106065 A CN 97106065A CN 97106065 A CN97106065 A CN 97106065A CN 1057693 C CN1057693 C CN 1057693C
- Authority
- CN
- China
- Prior art keywords
- hepatitis
- virus
- present
- parts
- converting negative
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The present invention relates to a hepatitis B virus converting negative tablet for inhibiting and deactivating hepatitis B viruses. The present invention is characterized in that the hepatitis B virus converting negative tablet is prepared by the following steps: mixing coptis root, scutellarjse barbatae, acori graminei, astragalus root, licorice, cordycep and ginseng according to a certain proportion; carrying out partial extraction, cleaning, baking, pulverization, tabletting and sugar coating. The present invention provides a treatment method which can treat both incidental aspects and fundamental aspects based on a patrimonial secret prescription for treating hepatic diseases by using Chinese medicines, integrating various advantages and combining modern science. The hepatitis B virus converting negative tablet is especially suitable for hepatitis B virus carriers, and has no toxic or side effect. The present invention also has the characteristics of low cost, short treatment cycle, etc.
Description
The invention belongs to treatment hepatopathy technical field, specifically a kind of hepatitis B virus converting negative tablet that adopts treatment by Chinese herbs hepatitis B disease.
Hepatopathy is more serious diseases to people, and according to the statistics made by the departments concerned, the hepatitis B virus infection person around us accounts for about 50%, and wherein surperficial anti-source carrier accounts for about 10%.People are once infectd hepatitis B virus, the necessary practice of each person having an individual portion of food, the active treatment carried out.At present, HBV infects and the medicine of liver cirrhosis is a lot of though be used to control, but its curative effect is different, for example: interferon, calf brain gland peptide, compound recipe Ganoderma applanatum (Pers. Ex Wallr) Pat. sheet, liver treasured or the like, although they are playing certain therapeutical effect to the hepatitis B disease in varying degrees, the weak point of their maximums is Zhi Qiben not with regard to being only to control its mark.
The purpose of this invention is to provide a kind of hepatitis B virus converting negative tablet to hepatitis B virus inhibition and deactivation.
The object of the present invention is achieved like this: the component and the ratio of weight and number thereof that are contained in its prescription are: Rhizoma Coptidis 10-18 part, Herba Portulacae Grandiflorae 8-12 part, Rhizoma Acori Graminei 5-8 part, Radix Astragali 6-8 part, Radix Glycyrrhizae 4-8 part, Cordyceps 3-6 part, Radix Ginseng 5-7 part.Production technology of the present invention is that those of ordinary skill is known, that is: extracting section, part cleaning, oven dry, pulverizing, film-making, sugar coating are made.Test by officinal requirement then.
The present invention is the Therapeutic Method in the treating both the principal and the secondary aspects of a disease at the same time of inheriting Chinese traditional treatment hepatopathy secret recipe handed down from one's ancestors, learn wildly from other's strong points and developing in conjunction with modern science, have strengthening the body resistance, promoting blood circulation to remove obstruction in the collateral, heat-clearing and toxic substances removing, enhancing body immunity, recover liver function, antiinflammatory, antiviral, promote superior efficacy such as " three Yang Yin commentaries on classics ", antitumor, alleviating pain, elimination abdominal distention effectively, the sheet of turning out cloudy of the present invention has no side effect.It is lower that the present invention also has a cost, the short point that waits of treatment cycle.
Below will the invention will be further described by concrete clinical example.Example 1
Choose seven Chinese medicines such as Rhizoma Coptidis 120 grams, Herba Portulacae Grandiflorae 80 grams, Rhizoma Acori Graminei 64 grams, the Radix Astragali 48 grams, Radix Glycyrrhizae 32 grams, Cordyceps 32 grams, Radix Ginseng 40 grams earlier, its production technology is to adopt those of ordinary skill known, that is: get earlier seven medicines each 50% extract, oven dry concentrates, and then with in addition through pulverizing and seven medicines of un-extracted fully mix, film-making, sugar coating and making again.Method of quality control:
Outward appearance: complete bright and clean, color and luster is even, hardness is suitable;
The uniformity: get tablet, remove sugar-coat, crushing should be mix homogeneously, color and luster unanimity;
Weight differential: before coating by the pharmacopeia inspection, weight differential must not be greater than ± 5.0%;
Disintegration: press the yellow method inspection of medicine, disintegration is in 30 minutes.
Medicine sanitary test: by " Chinese People's Liberation Army's medicine preparation standard)) 171 pages of method inspections of appendix, up to specification.
Usage and consumption: every day three times, each five, take 30 minutes ante cibum; Children's follows the doctor's advice, and 3 months is a course of treatment.
Sum up 285 routine hepatitis b virus carriers through clinical observation, after taking this medicine 3-6 month, HBsAg negative conversion rate 45.88%, effective percentage 97: 67%, HBeAg negative conversion rate 83.33%.Must contrast again with calf brain gland peptide, interferon and liver and to compare, show curative effect preferably.Its selected concrete clinical case is a case 1,2,3.Example 2
Choose seven Chinese medicines such as Rhizoma Coptidis 100 grams, Herba Portulacae Grandiflorae 80 grams, Rhizoma Acori Graminei 45 grams, the Radix Astragali 65 grams, Radix Glycyrrhizae 30 grams, Cordyceps 25 grams, Radix Ginseng 25 grams earlier, its production technology, method of quality control, usage and consumption all are same as example 1.And selected clinical case is a case 4,5,6.Case 1
Open * *, man, 8 years old.
Check the HBsAg positive in May, 1993, is diagnosed as hepatitis b virus carrier.Through giving hepatitis B virus converting negative tablet, 5,3/ day, 30 minutes ante cibum are oral, detect HBsAg after two courses of treatment and are negative, through follow-up observation recurrence (3 months each courses of treatment) so far.Case 2
Lee *, man, 32 years old.
Find the HBsAg positive in the health check-up, the HBeAg positive is diagnosed as hepatitis b virus carrier.Through giving hepatitis B virus converting negative tablet, 5,3/ day, 30 minutes ante cibum are oral, detect HBsAg after two courses of treatment and HBeAg all is negative, and result of laboratory test is still negative so far.Case 3
Slowly * *, woman, 28 years old.
The HBeAg positive is diagnosed as hepatitis b virus carrier in the health check-up.Through giving hepatitis B virus converting negative tablet, 5,3/ day, 30 minutes ante cibum are oral, detect HBeAg after two courses of treatment and are negative, so far recurrence always.Case 4
Single * *, man, 25 years old.
HBsAg, HBeAg in the health check-up, an anti-HBC are all positive, be diagnosed as hepatitis B virus carriers after, through giving 5 of hepatitis B virus converting negative tablets, 3/ day, 30 minutes ante cibum are oral, detect HBsAg, HBeAg after two courses of treatment, an anti-HBC is negative, recurrence always.Case 5
The king * *, man, 45 years old.
In physical examination, find the HBsAg positive, be diagnosed as hepatitis B virus carriers.Through giving 5 of hepatitis B virus converting negative tablets, 3/ day, 30 minutes ante cibum are oral, detect HBsAg after two courses of treatment and are negative, so far recurrence.Case 6
Open * *, man, 58 years old.
Find the HBeAg positive in 1995, be diagnosed as hepatitis B virus carriers.Through giving 5 of hepatitis B virus converting negative tablets, 3/ day, 30 minutes ante cibum are oral, detect HBeAg after four months and are negative, check twice all negative.
Claims (2)
1, a kind of being applicable to suppressed and the hepatitis B virus converting negative tablet of deactivation hepatitis B virus, it is characterized in that it can be made by the raw material components of following parts by weight: Rhizoma Coptidis 10-18 part Herba Portulacae Grandiflorae 8-12 part, Rhizoma Acori Graminei 5-8 part, Radix Astragali 6-8 part, Radix Glycyrrhizae 4-8 part, Cordyceps 3-6 part, Radix Ginseng 5-7 part.
2, hepatitis B virus converting negative tablet according to claim 1 is characterized in that the optimum weight portion rate of said components is: 15 parts of Rhizoma Coptidis, 10 parts of Herba Portulacae Grandifloraes, 8 parts of Rhizoma Acori Graminei, 6 parts of the Radixs Astragali, 4 parts in Radix Glycyrrhizae, 4 parts of Cordyceps, 5 parts of Radix Ginsengs.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN97106065A CN1057693C (en) | 1997-09-02 | 1997-09-02 | Hepatitis B virus converting negative tablet |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN97106065A CN1057693C (en) | 1997-09-02 | 1997-09-02 | Hepatitis B virus converting negative tablet |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1180568A CN1180568A (en) | 1998-05-06 |
| CN1057693C true CN1057693C (en) | 2000-10-25 |
Family
ID=5168341
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN97106065A Expired - Fee Related CN1057693C (en) | 1997-09-02 | 1997-09-02 | Hepatitis B virus converting negative tablet |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1057693C (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1085446A (en) * | 1993-06-29 | 1994-04-20 | 付军廷 | Hepatitis B virus converting negative tablet |
| CN1148977A (en) * | 1996-08-25 | 1997-05-07 | 重庆祥慧医药高新技术研究所 | Prescription of Yiganning capsule for curing hepatitis B and its production process |
-
1997
- 1997-09-02 CN CN97106065A patent/CN1057693C/en not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1085446A (en) * | 1993-06-29 | 1994-04-20 | 付军廷 | Hepatitis B virus converting negative tablet |
| CN1148977A (en) * | 1996-08-25 | 1997-05-07 | 重庆祥慧医药高新技术研究所 | Prescription of Yiganning capsule for curing hepatitis B and its production process |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1180568A (en) | 1998-05-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100349597C (en) | Chinese medicinal preparation for treating virus myocaraitis, its preparation method and quality control method | |
| KR20040043092A (en) | Novel medicinal herbal composition for treating liver diseases and hiv | |
| CN1248717C (en) | Liver benefiting Huangxuan Yigan Powder and its preparing process | |
| CN1150018C (en) | Medicine for treating tachy-arrhythmia | |
| CN1145240A (en) | Medicinal compsn. for prevention of Aids virus and cancer | |
| CN1223374C (en) | Chinese medicinal composition for treating hepatitis B | |
| CN1057693C (en) | Hepatitis B virus converting negative tablet | |
| CN1063954C (en) | Chinese patent medicine-powder preparation for curing hepatitis B | |
| CN1052157C (en) | Softing liver and contracting spleen tablet | |
| CN109700976B (en) | Qie and zedoary liver-protecting paste | |
| CN1085446A (en) | Hepatitis B virus converting negative tablet | |
| CN1127344C (en) | Oral pill for curing diabetes and its complication | |
| CN1116068C (en) | Medicine for treating ichthyosis and preparing process thereof | |
| CN111228388A (en) | A pharmaceutical composition for treating hepatopathy, and its application method | |
| CN110575521A (en) | Traditional Chinese medicine composition for treating chronic hepatitis B and hepatitis B-related compensatory cirrhosis and application | |
| CN1088589C (en) | Chinese medicine | |
| CN1241613C (en) | Chinese medicine for treating hepatopathy | |
| CN1286483C (en) | Chinese traditional drug pills capable of protecting liver, resisting hepatic fibrosis and expelling toxins | |
| CN1251714C (en) | Liver safeguarding pill | |
| CN1142391A (en) | Oral liquid | |
| CN1140283C (en) | Medicine for preventing and treating lupus erythematosus and other immunological disease | |
| CN1106856C (en) | Hepatosis treating medicine and its preparation | |
| CN1340353A (en) | Orally-applied medicine for treating hepatism and its preparing process | |
| CN1159057C (en) | Medicine for treating hepatitis, and preparing process thereof | |
| CN1887318A (en) | Chinese medicine tablet for inhibiting hepatitis B virus |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C06 | Publication | ||
| PB01 | Publication | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C19 | Lapse of patent right due to non-payment of the annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |